Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
Eisai Co., Ltd.
This study is a post-marketing surveillance of lenvatinib in participants with unresectable
thyroid cancer. The objectives of this study are to capture unknown adverse reactions,
incidences of adverse drug reaction, efficacy, factors considered to have effect to safety
and effectiveness, and incidences of hypertension, hemorrhagic events and thromboembolic
event, and liver disorder.
Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer Who Failed Gemcitabine-based Combination Chemotherapy
Active, not recruiting
Eisai Co., Ltd.
This is a multicenter, single arm, open-label study in participants with unresectable BTC
and disease progression or failure following one prior gemcitabine-based doublet
chemotherapy regimen (combination of gemcitabine and cisplatin, or gemcitabine and other
platinum agent/fluoropyrimidine agent). This study contains 3 phases: a Pre-treatment phase
that will last within 21 days; a Treatment phase that will consist of study treatment cycles
and tumor assessment conducted every 6-8 weeks; and a Follow-up phase that will begin
immediately after the Off-Treatment Visit and will continue as long as the participant is
alive, unless the participant withdraws consent, or until the End of Study.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.